Cabergoline for hyperprolactinemia: getting to the heart of it

Nachtigall, Lisa B.

doi:10.1007/s12020-017-1271-z

Cited by 15 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 Regardless, patients should be counseled on the potential association between high dose cabergoline and valvular heart disease, and echocardiographic monitoring should be considered for prolactinoma patients treated with higher-than-standard doses or for those with concerning signs or symptoms. 59,130…”

Section: Cardiac Valve Disease and Fibrosismentioning

confidence: 99%

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation Therapies

Wexler

Page-Wilson

2022

Preprint

View full text Add to dashboard Cite

Dopamine agonists are a key tool in the therapeutic arsenal of endocrinologists worldwide. They exert their effects by binding to dopamine 2 (D2) receptors expressed by pituitary tumor cells, to modulate hormonal secretion and tumor size. They are the established first-line treatment for prolactinomas which express high levels of D2 receptors. Growing data supports their use as an adjuvant treatment option for other pituitary tumors including growth hormone, adrenocorticotrophic hormones, thyroid hormone secreting adenomas and non-functional pituitary tumors, all of which have been shown to express D2 receptors as well, albeit to varying extents. For those pituitary tumors inadequately treated by dopamine agonist alone, combined agonism of D2 and somatostatin receptors, represent a new frontier in clinical development. Here we review the development and role of dopamine agonist for the treatment of prolactinomas, the literature supporting their adjuvant use for the treatment of all other pituitary tumors, and recent progress in the development of the next generation of chimeric compounds that target D2 and other receptor subtypes highly expressed on pituitary tumor cells.

show abstract

Section: Cardiac Valve Disease and Fibrosismentioning

confidence: 99%

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation Therapies

Wexler

Page-Wilson

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Cabergoline has a significant effect on dopamine receptors (D2) and has 43 hours as half-life. A recent study stated that there is better uterine flow of the blood and high response of ovulation in females that use it [8].…”

Section: Introductionmentioning

confidence: 99%

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Witwit

2022

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…When this inhibitory effect of dopamine is reduced, prolactin secretion will increase in addition to abnormalities in gonadotropins including luteinizing hormones (LH). (CE) which is a dopamine receptor agonist, with higher affinity to dopamine D2 receptors had improved uterine perfusion and achieved a better ovulatory response in (PCOS) patients [14], due to its ability to inhibit the vascular endothelial growth factor (VEGF) secretion in luteinized granulosa cells [15]. Other studies concluded that (CE) use could normalize androgen level and therefore improve the menstrual irregularity in women with (PCOS) [16].…”

Section: Introductionmentioning

confidence: 99%

Ovulation Induction in Patients with Polycystic Ovarian Syndrome (PCOS) & Hyperprolactinemia (HPRL): Efficacy of Letrozole (LE) Combined with Cabergoline (CE) in Comparison to (LE) Alone

Elbareg

2021

JGWH

View full text Add to dashboard Cite

Objectives: (PCOS) is the most common cause of anovulatory infertility, with majority of patients having mild (HPRL). (CE), a dopamine receptor agonist, inhibits prolactin secretion, leading to better ovulatory response. (LE), an aromatase inhibitor, without adverse effects on endometrium & induces fewer mature follicles with less risk of OHSS. Our aim was to investigate effects of combined (LE) & (CE) in comparison to (LE) alone on ovulation & clinical pregnancy rates in (PCOS) patients with (HPRL).Patients & Methods: 180 women with (PCOS) and of 22-38 years old, were enrolled in a hospital based clinical trial. Patients randomly allocated into 2 groups, (A&B). All with a serum prolactin > 32 ng/ml. Patients in (A): (92) were given (LE), 5mg for 5days: (3 -7 of the cycle)/3 cycles and (CE), 0.5mg weekly for 12 weeks. Those in (B): (88) received only (LE), same dose & duration as in (A). All patients were matched for their age and BMI. Exclusion criteria: other causes of (HPRL). Outcome measure: ovulation rate & detection of both chemical & clinical pregnancies by βhCG and ultrasound of fetal cardiac activity, 2-4 weeks after missed period. Follow-up for 6 months. Data analysis by using SPSS version for windows, P-value significant if (< 0.05).Results: 3 patients from (A) & 5 from (B) had drug side effects and were excluded. None of patients were lost during the follow-up period. In (A), difference between mean serum prolactin level before & after treatment was statistically significant (P<0.001): 48.3±4.2ng/ml and 8.1±5.2ng/ml, respectively. No significant decrease of prolactin level in (B) (P >0.05). After treatment, BMI in (A) 24.1± 3.2, & 24.2 ± 3.6 in (B) (P=0.567). (56.2%) of women in (A) became regularly menstruating but only (30.1%) in (B) (P< 0.05). Ovulation rate was higher in (A) (50.6%) in comparison to (B) (26.5%), (P<0.05). Clinical pregnancy rate in (A) (41.6%) and (21.6%) in (B) (P<0.05). Neither twin pregnancy, nor OHSS were recorded in both groups. Conclusion:The combination of (LE) & (CE) is superior to (LE) alone in management of anovulatory patients with (PCOS) and should be used as the first-line treatment for them.

show abstract

Cabergoline for hyperprolactinemia: getting to the heart of it

Cited by 15 publications

References 20 publications

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation Therapies

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation Therapies

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Ovulation Induction in Patients with Polycystic Ovarian Syndrome (PCOS) & Hyperprolactinemia (HPRL): Efficacy of Letrozole (LE) Combined with Cabergoline (CE) in Comparison to (LE) Alone

Contact Info

Product

Resources

About